Rfviii
Blood Coagulation Disorders
BayerPhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Blood Coagulation Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Factor Ix National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | BB |
tu7710 TiumBio Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
Rfviii is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →